StatementBusinessSegments [Axis] Plasma Collection Centers [Member] Corporate [Member] Statement, Equity Components [Axis] Common Stock Additional Paid-in Capital Accumulated Deficit Range [Axis] Minimum [Member] Maximum [Member] Income Statement Location [Axis] Research and Development Expense Selling, General and Administrative Expense Plasma centers [Member] Tax Credit Carryforward [Axis] Federal State Non-Voting Common Stock Class of Stock [Axis] Antidilutive Securities [Axis] Stock Options Warrants Property, Plant and Equipment, Type [Axis] Manufacturing and laboratory equipment Office equipment and computer software Furniture and fixtures Leasehold improvements Land Buildings Construction in process Finite-Lived Intangible Assets by Major Class [Axis] Trademark and other intangible rights related to Nabi-HB Right to intermediates Customer contract $1.34 - $2.06 $2.96 - $4.60 $4.72 - $7.21 $7.56 - $10.80 Cost of goods sold ADMA BioManufacturing Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets: Cash and cash equivalents Accounts receivable, net Inventories Prepaid expenses and other current assets Restricted cash Total current assets Property and equipment, net Intangible assets, net Goodwill Assets to be transferred under purchase agreement Restricted cash Deposits and other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Current portion of deferred revenue Current portion of capital lease obligation Total current liabilities Notes payable, net of discount End of term liability, notes payable Deferred revenue, net of current portion Note payable - related party, net of discount Obligation to transfer assets under purchase agreement Capital lease obligation Other non-current liabilities TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding Common Stock Additional Paid-in Capital Accumulated Deficit TOTAL STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Stockholders Equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value Common stock, shares authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] REVENUES: Product revenue License revenue Other revenue Total Revenues OPERATING EXPENSES: Cost of product revenue (exclusive of amortization expense shown below) Research and development Plasma center operating expenses Asset impairment charge Amortization of intangibles Selling, general and administrative Total operating expenses LOSS FROM OPERATIONS OTHER INCOME (EXPENSE): Interest income Interest expense Loss on extinguishment of debt Other expense Other expense, net NET LOSS BASIC AND DILUTED LOSS PER COMMON SHARE WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted Equity Components [Axis] Beginning Balance, Amount Beginning Balance, Shares Stock-based compensation Shares issued in connection with acquisition, Amount Shares issued in connection with acquisition, Shares Warrants issued in connection with note payable Issuance of common stock, net of offering expenses, Amount Issuance of common stock, net of offering expenses, Shares Stock options exercised, Amount Stock options exercised, Shares Retirement of non-voting common stock, Amount Retirement of non-voting common stock, Shares Net loss Ending Balance, Amount Ending Balance, Shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Loss on disposal of fixed assets Amortization of debt discount Loss on extinguishment of debt Amortization of license revenue Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other current assets Deposits and other assets Accounts payable Accrued expenses Other current and non-current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Sales of short-term investments Purchase of property and equipment Cash acquired in acquisition transaction Net cash (used in) provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Principal payments on note payable Payment of end of term fee Proceeds from issuance of common stock, net of offering expenses Proceeds from the exercise of stock options Proceeds from issuance of related party note payable Proceeds from issuance of note payable Payment of debt issuance costs Payments on capital lease obligations Payments of leasehold improvement loan Net cash provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents, including restricted cash - beginning of year Cash and cash equivalents, including restricted cash - end of year Organization, Consolidation and Presentation of Financial Statements [Abstract] 1. ORGANIZATION AND BUSINESS Accounting Policies [Abstract] 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Combinations [Abstract] 3. ACQUISITION Inventory Disclosure [Abstract] 4. INVENTORIES Property, Plant and Equipment [Abstract] 5. PROPERTY AND EQUIPMENT Intangible Assets, Net (Excluding Goodwill) [Abstract] 6. INTANGIBLE ASSETS Debt Disclosure [Abstract] 7. NOTES PAYABLE Stockholders' Equity Attributable to Parent [Abstract] 8. STOCKHOLDERS' EQUITY Related Party Transactions [Abstract] 9. RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] 10. COMMITMENTS AND CONTINGENCIES Income Tax Disclosure [Abstract] 11. INCOME TAXES Segment Reporting [Abstract] 12. SEGMENTS Retirement Benefits [Abstract] 13. OTHER EMPLOYEE BENEFITS Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] 14. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Concentration Risks, Types, No Concentration Percentage [Abstract] 15. CONCENTRATIONS Quarterly Financial Information Disclosure [Abstract] 16. QUARTERLY FINANCIAL INFORMATION (UNAUDITED) Subsequent Events [Abstract] 17. SUBSEQUENT EVENTS Principles of Consolidation and Basis of presentation Use of estimates Cash and cash equivalents Restricted cash Accounts receivable Inventories Property and equipment Goodwill Impairment of long-lived assets Revenue recognition Cost of product revenue Research and development expenses Advertising and marketing expenses Stock-based compensation Income taxes Earnings (Loss) Per Share Business Combinations Fair value of financial instruments Recent Accounting Pronouncements Schedule of goodwill Schedule of dilutive securities Purchase price allocation Schedule of assets and liabilities assumed Pro forma information Schedule of inventory Schedule of property and equipment Schedule of intangible assets Intangible asset future aggregate amortization expense Summary of outstanding senior notes payable Reconciliation of cash, cash equivalents and restricted cash Discount on the Tranche One Note Summary of the outstanding related party note payable Schedule of assumptions Schedule of stock option activity Summary of outstanding and exercisable options by price range Stock-based compensation expense Schedule of related party transactions Future minimum lease payments Schedule of reconciliation of income taxes Schedule of deferred tax asset Summarized segment financial information Schedule of supplemental cash flow information Quarterly financial information Accumulated deficit Goodwill, beginning balance Goodwill recorded in connection with the acquisition of the Biotest Assets Goodwill, ending balance Potentially dilutive securities Advertising and marketing expenses Issuance of 12,886,740 shares of common stock (voting and non-voting) valued at $3.66 per share Transfer of two plasma collection centers Total purchase price Cash Inventory Land and buildings Property and equipment Assets held for sale Other current assets Trademark and other intangible rights to Nabi-HB Right to intermediates Customer contract Goodwill Liabilities assumed Revenues: As reported Proforma Net loss As reported Proforma Basic and diluted net loss per share: As reported Pro forma, basic Pro forma, diluted Transaction closing costs Raw materials Work-in-progress Finished goods Total inventories Property, plant and equipments, gross Less: Accumulated depreciation and amortization Property, plant and equipments, net Depreciation and amortization expense Cost Accumulated amortization Net 2019 2020 2021 2022 2023 Notes payable Less: Debt discount Less: Current portion Senior notes payable Restricted cash included in current assets Restricted cash included in long-term assets Total cash, cash equivalents and restricted cash as shown in the consolidated statements of cash flows Facility fee Deferred financing fees Tranche One Warrants Total debt discount at Marathon Closing Date Related party note payable to Biotest Less: Debt discount Note payable - related party Expected Term Volatility Dividend yield Risk-free interest rate Shares Outstanding at beginning of period Forfeited Expired Granted Exercised Outstanding at end of period and expected to vest Options exercisable Weighted Average Exercise Price Outstanding at beginning of period Forfeited Expired Granted Exercised Outstanding at end of period and expected to vest Options exercisable Options outstanding Options outstanding, weighted average remaining contractual life Options outstanding, weighted average exercise price Options outstanding, aggregate intrinsic value Options exercisable Options exercisable, weighted average remaining contractual life Options exercisable, weighted average exercise price Options exercisable, aggregate intrinsic value Total stock-based compensation expense Total unrecognized compensation expense related to unvested options Total unrecognized compensation expense related to unvested options, period Exercisable options intrinsic value Sale and purchase of plasma Product revenue Purchases Interest expense Accounts receivable Accounts payable Accrued expenses Note payable, net of discount Accrued interest Deferred revenue Rent expense 2019 2020 2021 2022 2023 Thereafter Total Rent expense Benefit at U.S. Federal statutory rate State taxes - deferred Increase in valuation allowance Research and development credits Federal tax reform rate change Decrease in federal net operating loss Decrease in federal research and development credits Other Benefit for income taxes Federal and state net operating loss carryforwards Federal and state research credits Interest expense limitations carryforwards Transaction costs Deferred revenue Accrued expenses and other Total gross deferred tax assets Less: valuation allowance for deferred tax assets Net deferred tax assets Net operating loss carryforwards Research and development tax credit carryforwards Segments [Axis] Revenues Cost of product revenue Gross (loss) profit Loss from operations Interest and other expense, net Capital expenditures Depreciation and amortization expense Total assets SUPPLEMENTAL INFORMATION: Cash paid for interest Noncash Financing and Inesting Activities: Equipment acquired reflected in accounts payable and accrued liabilities Equipment acquired through capital lease Warrants issued in connection with note payable End of term liability for senior notes payable Assets acquired through the issuance of common stock and liabilities assumed License and other revenue Total Revenues Total operating expenses LOSS FROM OPERATIONS Other expense, net Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Assets, Current Restricted Cash, Noncurrent Assets Liabilities, Current Liabilities Common Stock, Value, Issued Additional Paid in Capital Stockholders' Equity Attributable to Parent Liabilities and Equity Interest Expense Shares, Issued Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property GainsLossOnExtinguishmentOfDebt Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Operating Assets Increase (Decrease) in Accounts Payable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Payments for Other Fees Payments of Debt Issuance Costs Repayments of Debt and Capital Lease Obligations Repayments of Other Debt Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Marketing and Advertising Expense Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Acquisition, Goodwill, Expected Tax Deductible Amount Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Acquisition, Pro Forma Net Income (Loss) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Debt Instrument, Unamortized Discount Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriod Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price PlasmaProductRevenue Accounts Receivable, Related Parties Accounts Payable, Related Parties Accrued Liabilities, Fair Value Disclosure Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Rent Expense, Net Deferred Tax Assets, Deferred Income Deferred Tax Assets, Valuation Allowance WarrantsIssuedInConnectionWithNotePayable